STOCK TITAN

Ventyx Biosciences to Participate in the Jefferies Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Ventyx Biosciences, a clinical-stage biopharmaceutical company, will present a company overview during the Jefferies Healthcare Conference on June 8, 2022. CEO Raju Mohan will lead the presentation scheduled from 4:00-4:25 PM ET in New York, NY. The management team will also engage with investors at the event. A webcast of the presentation will be available on the Ventyx website and can be accessed for 30 days after the conference. Ventyx focuses on innovative oral therapies for inflammatory diseases, with a pipeline that includes programs targeting TYK2, S1P1R, and NLRP3.

Positive
  • None.
Negative
  • None.

ENCINITAS, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview during a fireside chat at the Jefferies Healthcare Conference being held June 8-10, 2022.

  • Event: Jefferies Healthcare Conference
    Location: New York, NY
    Date: Wednesday, June 8, 2022
    Time: 4:00-4:25 PM ET

Members of the Ventyx management team will also host investor meetings during the conference.

A webcast of the fireside chat will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of each event for 30 days.

About Ventyx Biosciences

Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes three clinical-stage programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit www.ventyxbio.com.

Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com 


FAQ

When is Ventyx's presentation at the Jefferies Healthcare Conference?

Ventyx's presentation at the Jefferies Healthcare Conference is scheduled for June 8, 2022, from 4:00 to 4:25 PM ET.

Who will represent Ventyx at the Jefferies Healthcare Conference?

Raju Mohan, the CEO of Ventyx, will provide a company overview during the conference.

Where is the Jefferies Healthcare Conference taking place?

The Jefferies Healthcare Conference will be held in New York, NY.

Will there be a webcast available for Ventyx's presentation?

Yes, a webcast of Ventyx's presentation will be available on their website and will be accessible for 30 days after the event.

What is Ventyx focusing on in its drug development?

Ventyx focuses on developing innovative oral therapies for inflammatory diseases with significant unmet medical needs.

Ventyx Biosciences, Inc.

NASDAQ:VTYX

VTYX Rankings

VTYX Latest News

VTYX Stock Data

153.71M
70.67M
3.31%
91.61%
11.85%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO